Connor, Clark & Lunn Investment Management Ltd. Xeris Biopharma Holdings, Inc. Transaction History
Connor, Clark & Lunn Investment Management Ltd.
- $18.8 Billion
- Q3 2024
A detailed history of Connor, Clark & Lunn Investment Management Ltd. transactions in Xeris Biopharma Holdings, Inc. stock. As of the latest transaction made, Connor, Clark & Lunn Investment Management Ltd. holds 83,108 shares of XERS stock, worth $283,398. This represents 0.0% of its overall portfolio holdings.
Number of Shares
83,108Holding current value
$283,398% of portfolio
0.0%Shares
3 transactions
Others Institutions Holding XERS
# of Institutions
142Shares Held
59.9MCall Options Held
148KPut Options Held
45.7K-
Black Rock Inc. New York, NY10.3MShares$35.2 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA7.77MShares$26.5 Million0.0% of portfolio
-
Caxton Corp Princeton, NJ5.11MShares$17.4 Million62.59% of portfolio
-
Center Book Partners LP Greenwich, CT3.48MShares$11.9 Million0.64% of portfolio
-
Geode Capital Management, LLC Boston, MA3.33MShares$11.4 Million0.0% of portfolio
About Xeris Biopharma Holdings, Inc.
- Ticker XERS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 135,956,992
- Market Cap $464M
- Description
- Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies for patient populations in endocrinology, neurology, and gastroenterology. The company markets Gvoke, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia; and Keveyis, a therapy for the treatment of hyperkalemic, h...